AIDS
Conditions
Interventions
A: Time-driven group:Tenofovir 300mg p.o. qd for 96 wks
B: Event-driven group:Tenofovir 300mg p.o. at 48-24 hrs before sex and another 300mg po 2h after sex
C: Control:No drug and Standard HIV prevention intervention services provided as other groups
Sponsors
National Base for Drug Clinical Trials, First Affiliated Hospital, Chongqing Medical University
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Signed informed consent; (2) Aged 18 to 65 years; (3) Anti-HIV Negative; (4) Sexual behaviour: An average of once every two weeks or more; (5) One before before trial, has one or more same-sex-partner; (6) Compliance to guidance of drug use and follow-up; (7) Accept to participate in trial for 96 weeks.
Exclusion criteria
Exclusion criteria: (1) Anti-HIV: Postive in screening; (2) HBsAg or anti-HBc: Positive in screening; (3) With severe heart diseases, liver diseases(AST, ALT more than 1.5 times to the upper limit of normal), kidney disorders(BUN, Cr exceed the upper limit of normal) or hematopoietic dysfunction disorders, bleeding tendency and hemorrhagic disease patients; (4) With advanced cancer; (5) Alcoholism within 1 year; (6) With serious diseases that the researchers believe inappropriate to include; (7) Received other related drugs within 3 months; (8) With severe allergies; (9) Unable or unwilling to provide informed consent or who can not comply with the guidance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIV-1 Antibody;HIV-2 Antibody; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine examination;Urinary routine examination;Blood biochemistry examination;Plasma HIV RNA;CD4 cell count; | — |
Countries
China
Contacts
Public ContactAilong Huang
Chongqing Medical University
Outcome results
None listed